Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription 30.08.2021 1 AJR Am J Roentgenol 1 Am J Clin Pathol 1 Am J Epidemiol 1 Ann Oncol 8 Ann Surg Oncol 1 BMC Cancer 3 Breast Cancer 2 Breast Cancer Res 2 Breast Cancer Res Treat 3 Breast J 5 Cancer 2 Cancer Chemother Pharmacol 2 Cancer Epidemiol Biomarkers Prev 2 Cancer Lett 2 Cancer Res 1 Cell 4 Clin Breast Cancer 1 Clin Cancer Res 2 Curr Treat Options Oncol 2 Eur J Cancer 3 Eur Radiol 1 Gene 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Biol Chem 1 J Clin Oncol 1 J Nucl Med 1 J Surg Oncol 3 NPJ Breast Cancer 1 Oncology 4 PLoS One 1 Proc Natl Acad Sci U S A 3 Radiol Imaging Cancer 1 Semin Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LEE HJ, Lee JE, Jeong WG, Ki SY, et al
   Human Epidermal Growth Factor Receptor Type 2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.
   AJR Am J Roentgenol. 2021 Aug 25. doi: 10.2214/AJR.21.26400.
   PubMed         Abstract available
   
   

   
   Am J Clin Pathol

2. ZHANG H, Moisini I, Turner BM, Wang X, et al
   Significance of HER2 in Microinvasive Breast Carcinoma.
   Am J Clin Pathol. 2021;156:155-165.
   PubMed         Abstract available
   
   

   
   Am J Epidemiol

3. LASH TL, Ahern TP, Collin LJ, Fox MP, et al
   Bias Analysis Gone Bad.
   Am J Epidemiol. 2021;190:1604-1612.
   PubMed         Abstract available
   
   

   
   Ann Oncol

4. SCHRODI S, Braun M, Andrulat A, Harbeck N, et al
   Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort.
   Ann Oncol. 2021 Aug 19. pii: S0923-7534(21)04218.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. SARIDAKIS A, Berger ER, Harigopal M, Park T, et al
   Apocrine Breast Cancer: Unique Features of a Predominantly Triple-Negative Breast Cancer.
   Ann Surg Oncol. 2021 Aug 23. pii: 10.1245/s10434-021-10518.
   PubMed         Abstract available
   
   
6. YUAN Q, Hou J, Zhou R, Zheng L, et al
   ASO Visual Abstract: Stepwise Limited Axillary Lymph Node Dissection Based on Lymphatic Drainage from the Breast to Decrease Breast Cancer-Related Lymphedema: A Randomized Controlled Trial.
   Ann Surg Oncol. 2021 Aug 24. pii: 10.1245/s10434-021-10703.
   PubMed        
   
   
7. CHE BAKRI NA, Kwasnicki RM, Dhillon K, Khan N, et al
   ASO Author Reflections: Improving Management of Upper Limb Complications after Breast Cancer Treatments.
   Ann Surg Oncol. 2021 Aug 24. pii: 10.1245/s10434-021-10603.
   PubMed        
   
   
8. OROZCO JIJ, Chang SC, Matsuba C, Ensenyat-Mendez M, et al
   ASO Visual Abstract: Is the 21-Gene Recurrence Score on Core Needle Biopsy Equivalent to Surgical Specimen in Early-Stage Breast Cancer? : A Comparison of Gene Expression Between Paired Core Needle Biopsy and Surgical Specimens.
   Ann Surg Oncol. 2021 Aug 25. pii: 10.1245/s10434-021-10589.
   PubMed        
   
   
9. DILLON J, Thomas SM, Rosenberger LH, DiLalla G, et al
   ASO Visual Abstract: Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery-How Low is "Low Risk"?
   Ann Surg Oncol. 2021 Aug 25. pii: 10.1245/s10434-021-10612.
   PubMed        
   
   
10. LIM DW, Hong NJL
    ASO Author Reflections: Identifying pCR After Neoadjuvant Chemotherapy: The Key to Treatment De-escalation in Breast Cancer.
    Ann Surg Oncol. 2021 Aug 25. pii: 10.1245/s10434-021-10699.
    PubMed        
    
    
11. FAYANJU OM
    Black-White Differences in Treatment Receipt and Outcome for Triple-Negative Breast Cancer: The Competing Contributions of Access, Bias, and Biology.
    Ann Surg Oncol. 2021 Aug 26. pii: 10.1245/s10434-021-10697.
    PubMed        
    
    
12. WILKE LG, Nguyen TT, Yang Q, Hanlon BM, et al
    Analysis of the Impact of the COVID-19 Pandemic on the Multidisciplinary Management of Breast Cancer: Review from the American Society of Breast Surgeons COVID-19 and Mastery Registries.
    Ann Surg Oncol. 2021 Aug 24. pii: 10.1245/s10434-021-10639.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. DAI YH, Wang YF, Shen PC, Lo CH, et al
    Gene-associated methylation status of ST14 as a predictor of survival and hormone receptor positivity in breast Cancer.
    BMC Cancer. 2021;21:945.
    PubMed         Abstract available
    
    

    
    Breast Cancer

14. SUZUKI Y, Wenwen W, Ohta T, Hayashi SI, et al
    Correction to: Molecular targeted drugs resistance impairs doublestrand break repair and sensitizes ERpositive breast cancer to PARP inhibitors.
    Breast Cancer. 2021 Aug 22. pii: 10.1007/s12282-021-01288.
    PubMed        
    
    
15. LAI J, Chen B, Li Y, Lin X, et al
    Integrated analysis of cell cycle-related genes in HR+/HER2- breast cancer.
    Breast Cancer. 2021 Aug 27. pii: 10.1007/s12282-021-01289.
    PubMed         Abstract available
    
    
16. BRANDS-APPELDOORN ATPM, Maaskant-Braat AJG, Janssen L, van Osch LADM, et al
    Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy.
    Breast Cancer. 2021 Aug 26. pii: 10.1007/s12282-021-01287.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

17. NEVEN P, Rugo HS, Tolaney SM, Iwata H, et al
    Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Breast Cancer Res. 2021;23:87.
    PubMed         Abstract available
    
    
18. ROMINE PE, Peterson LM, Kurland BF, Byrd DW, et al
    (18)F-fluorodeoxyglucose (FDG) PET or (18)F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
    Breast Cancer Res. 2021;23:88.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

19. GAL R, Monninkhof EM, van Gils CH, Groenwold RHH, et al
    Effects of exercise in breast cancer patients: implications of the trials within cohorts (TwiCs) design in the UMBRELLA Fit trial.
    Breast Cancer Res Treat. 2021 Aug 24. pii: 10.1007/s10549-021-06363.
    PubMed         Abstract available
    
    
20. XU J, Keenan TE, Overmoyer B, Tung NM, et al
    Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations.
    Breast Cancer Res Treat. 2021 Aug 20. pii: 10.1007/s10549-021-06292.
    PubMed         Abstract available
    
    

    
    Breast J

21. ALLALI S, Servois V, Beddok A, Fourquet A, et al
    Evaluation of the early adverse effects of radiotherapy in breast cancer patients with COVID-19: Prospective single institutional study.
    Breast J. 2021 Aug 25. doi: 10.1111/tbj.14282.
    PubMed         Abstract available
    
    
22. LEHRBERG A, Sebai M, Finn D, Lee D, et al
    Trends, survival outcomes, and predictors of nonadherence to mastectomy guidelines for nonmetastatic inflammatory breast cancer.
    Breast J. 2021 Aug 24. doi: 10.1111/tbj.14283.
    PubMed         Abstract available
    
    
23. MASOOD S
    Why proper characterization of breast cancer subtypes makes a difference in patient care.
    Breast J. 2021 Aug 24. doi: 10.1111/tbj.14285.
    PubMed        
    
    

    
    Cancer

24. FEDEWA SA, Cotter MM, Wehling KA, Wysocki K, et al
    Changes in breast cancer screening rates among 32 community health centers during the COVID-19 pandemic.
    Cancer. 2021 Aug 26. doi: 10.1002/cncr.33859.
    PubMed         Abstract available
    
    
25. HENDERSON V, Ganschow P, Wang C, Hoskins KF, et al
    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?
    Cancer. 2021 Aug 23. doi: 10.1002/cncr.33867.
    PubMed        
    
    
26. YAFFE MJ
    Looking at breast cancer through the ethnic and racial lens-one size definitely does not fit all.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33841.
    PubMed         Abstract available
    
    
27. HENDRICK RE, Monticciolo DL, Biggs KW, Malak SF, et al
    Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US Women.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33846.
    PubMed         Abstract available
    
    
28. SEEWALDT VL, Bernstein L
    The perils of generalization: Rethinking breast cancer screening guidelines for young women of color.
    Cancer. 2021 Aug 24. doi: 10.1002/cncr.33840.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

29. MAILLARD M, Eche-Gass A, Ung M, Brice A, et al
    Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
    Cancer Chemother Pharmacol. 2021;87:579-583.
    PubMed         Abstract available
    
    
30. SHEN X, Sun X, Chen H, Lu B, et al
    Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition.
    Cancer Chemother Pharmacol. 2021;87:487-499.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

31. OSKAR S, Kehm R, Terry MB
    Breast Tissue Composition-Why It Matters and How Can We Measure It More Accurately in Epidemiology Studies.
    Cancer Epidemiol Biomarkers Prev. 2021;30:590-592.
    PubMed         Abstract available
    
    
32. ROSNER B, Tamimi RM, Kraft P, Gao C, et al
    Simplified Breast Risk Tool Integrating Questionnaire Risk Factors, Mammographic Density, and Polygenic Risk Score: Development and Validation.
    Cancer Epidemiol Biomarkers Prev. 2021;30:600-607.
    PubMed         Abstract available
    
    

    
    Cancer Lett

33. LA CAMERA G, Gelsomino L, Malivindi R, Barone I, et al
    Adipocyte-derived extracellular vesicles promote breast cancer cell malignancy through HIF-1alpha activity.
    Cancer Lett. 2021 Aug 20. pii: S0304-3835(21)00410.
    PubMed         Abstract available
    
    
34. WANG Y, Liang Q, Lei K, Zhu Q, et al
    Targeting MEX3A attenuates metastasis of breast cancer via beta-catenin signaling pathway inhibition.
    Cancer Lett. 2021;521:50-63.
    PubMed         Abstract available
    
    

    
    Cancer Res

35. ZUO H, Yang D, Wan Y
    Fam20C regulates bone resorption and breast cancer bone metastasis through osteopontin and BMP4.
    Cancer Res. 2021 Aug 25. pii: 0008-5472.CAN-20-3328.
    PubMed         Abstract available
    
    
36. PRABHU JS, Korlimarla A, Rajarajan S, Alexander A, et al
    Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer.
    Cancer Res. 2021;81.
    PubMed         Abstract available
    
    

    
    Cell

37. PRENTZELL MT, Rehbein U, Cadena Sandoval M, De Meulemeester AS, et al
    G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling.
    Cell. 2021;184:655-674.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

38. DE WILD SR, Simons JM, Vrancken Peeters MTFD, Smidt ML, et al
    MINImal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX).
    Clin Breast Cancer. 2021 Jul 26. pii: S1526-8209(21)00199.
    PubMed         Abstract available
    
    
39. YADAV SK, Silwal S, Yadav S, Krishnamoorthy G, et al
    A Systematic Comparison of Overall Survival Between Men and Women With Triple Negative Breast Cancer.
    Clin Breast Cancer. 2021 Jul 18. pii: S1526-8209(21)00178.
    PubMed         Abstract available
    
    
40. NORMAN H, Lee KT, Stearns V, Alcorn SR, et al
    Incidence and Severity of Myelosuppression With Palbociclib After Palliative Bone Radiation in Advanced Breast Cancer: A Single Center Experience and Review of Literature.
    Clin Breast Cancer. 2021 Jul 27. pii: S1526-8209(21)00202.
    PubMed         Abstract available
    
    
41. YE F, Wen J, Yang A, Wang Y, et al
    The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis.
    Clin Breast Cancer. 2021 Jul 21. pii: S1526-8209(21)00174.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

42. JHAVERI K, Juric D, Yap YS, Cresta S, et al
    A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-1095.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

43. VAIDYANATHAN A, Kaklamani V
    Understanding the Clinical Implications of Low Penetrant Genes and Breast Cancer Risk.
    Curr Treat Options Oncol. 2021;22:85.
    PubMed         Abstract available
    
    
44. NESBIT EG, Donnelly ED, Strauss JB
    Treatment Strategies for Oligometastatic Breast Cancer.
    Curr Treat Options Oncol. 2021;22:94.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

45. MOBUS V, Luck HJ, Ladda E, Klare P, et al
    Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
    Eur J Cancer. 2021;156:138-148.
    PubMed         Abstract available
    
    
46. KAHAN Z, Gil-Gil M, Ruiz-Borrego M, Carrasco E, et al
    Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
    Eur J Cancer. 2021;156:70-82.
    PubMed         Abstract available
    
    

    
    Eur Radiol

47. CORNFORD E, Cheung S, Press M, Kearins O, et al
    Optimum screening mammography reading volumes: evidence from the NHS Breast Screening Programme.
    Eur Radiol. 2021;31:6909-6915.
    PubMed         Abstract available
    
    
48. LEE SE, Han K, Kim EK
    Application of artificial intelligence-based computer-assisted diagnosis on synthetic mammograms from breast tomosynthesis: comparison with digital mammograms.
    Eur Radiol. 2021;31:6929-6937.
    PubMed         Abstract available
    
    
49. TANG WJ, Kong QC, Cheng ZX, Liang YS, et al
    Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase.
    Eur Radiol. 2021 Aug 24. pii: 10.1007/s00330-021-08173.
    PubMed         Abstract available
    
    

    
    Gene

50. GUNES CE, Guclu E, Vural H, Kurar E, et al
    Knockdown of lncRNA ZEB2NAT suppresses epithelial mesenchymal transition, metastasis and proliferation in breast cancer cells.
    Gene. 2021 Aug 18:145904. doi: 10.1016/j.gene.2021.145904.
    PubMed         Abstract available
    
    

    
    Int J Cancer

51. ZHENG KH, Zhu K, Wactawski-Wende J, Freudenheim JL, et al
    Caffeine Intake from Coffee and Tea and Invasive Breast Cancer Incidence among Postmenopausal Women in the Women's Health Initiative.
    Int J Cancer. 2021 Aug 21. doi: 10.1002/ijc.33771.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

52. LIU HC, Viswanath DI, Pesaresi F, Xu Y, et al
    Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
    Int J Radiat Oncol Biol Phys. 2021;110:492-506.
    PubMed         Abstract available
    
    
53. HANNOUN-LEVI JM, Gal J, Van Limbergen E, Chand ME, et al
    Salvage Mastectomy Versus Second Conservative Treatment for Second Ipsilateral Breast Tumor Event: A Propensity Score-Matched Cohort Analysis of the GEC-ESTRO Breast Cancer Working Group Database.
    Int J Radiat Oncol Biol Phys. 2021;110:452-461.
    PubMed         Abstract available
    
    

    
    J Biol Chem

54. RYAN K, Bolanos B, Smith M, Palde PB, et al
    Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
    J Biol Chem. 2021;296:100251.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

55. SACKS GD, Morrow M
    Addressing the Dilemma of Contralateral Prophylactic Mastectomy With Behavioral Science.
    J Clin Oncol. 2021;39:269-272.
    PubMed        
    
    

    
    J Nucl Med

56. IQBAL R, Yaqub M, Oprea-Lager DE, Liu Y, et al
    Biodistribution of (18)F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262500. doi: 10.2967/jnumed.121.262500.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

57. BILANI N, Yaghi M, Singh Jabbal I, Elson L, et al
    Survival benefit of a combined surgical approach in patients with metastatic breast cancer.
    J Surg Oncol. 2021 Aug 26. doi: 10.1002/jso.26656.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

58. BARROSO-SOUSA R, Keenan TE, Li T, Tayob N, et al
    Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study.
    NPJ Breast Cancer. 2021;7:110.
    PubMed         Abstract available
    
    
59. LIU YL, Bager CL, Willumsen N, Ramchandani D, et al
    Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer.
    NPJ Breast Cancer. 2021;7:108.
    PubMed         Abstract available
    
    
60. MATIS TS, Zayed N, Labraki B, de Ladurantaye M, et al
    Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families.
    NPJ Breast Cancer. 2021;7:109.
    PubMed         Abstract available
    
    

    
    Oncology

61. BERGER NF, Zimmerman BS, Tharakan S, Suchman K, et al
    Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and >/=31.
    Oncology. 2021 Aug 23:1-4. doi: 10.1159/000517843.
    PubMed         Abstract available
    
    

    
    PLoS One

62. AHN HS, Kim SH, Kim JY, Park CS, et al
    Image quality and diagnostic value of diffusion-weighted breast magnetic resonance imaging: Comparison of acquired and computed images.
    PLoS One. 2021;16:e0247379.
    PubMed         Abstract available
    
    
63. ARNEJA J, Brooks JD
    The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada.
    PLoS One. 2021;16:e0256536.
    PubMed         Abstract available
    
    
64. HEENAYE-MAMODE KHAN M, Boodoo-Jahangeer N, Dullull W, Nathire S, et al
    Multi- class classification of breast cancer abnormalities using Deep Convolutional Neural Network (CNN).
    PLoS One. 2021;16:e0256500.
    PubMed         Abstract available
    
    
65. PORCIELLO G, Montagnese C, Crispo A, Grimaldi M, et al
    Correction: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial.
    PLoS One. 2021;16:e0256944.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

66. AZUMA K, Ikeda K, Suzuki T, Aogi K, et al
    TRIM47 activates NF-kappaB signaling via PKC-epsilon/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

67. DAIMIEL NARANJO I, Lo Gullo R, Morris EA, Larowin T, et al
    High-Spatial-Resolution Multishot Multiplexed Sensitivity-encoding Diffusion-weighted Imaging for Improved Quality of Breast Images and Differentiation of Breast Lesions: A Feasibility Study.
    Radiol Imaging Cancer. 2020;2:e190076.
    PubMed         Abstract available
    
    
68. JAIN R, Katz DR, Kapoor AD
    The Clinical Utility of a Negative Result at Molecular Breast Imaging: Initial Proof of Concept.
    Radiol Imaging Cancer. 2020;2:e190096.
    PubMed         Abstract available
    
    
69. CHEN Y, James JJ, Cornford EJ, Jenkins J, et al
    The Relationship between Mammography Readers' Real-Life Performance and Performance in a Test Set-based Assessment Scheme in a National Breast Screening Program.
    Radiol Imaging Cancer. 2020;2:e200016.
    PubMed         Abstract available
    
    

    
    Semin Oncol

70. CAVALCANTE FP
    Breast cancer care: Looking for the new normal.
    Semin Oncol. 2021 Aug 7. pii: S0093-7754(21)00052.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: